Serina Therapeutics Announces FDA Feedback Supports Registrational Trial Design of SER-252 in Advanced Parkinson's Disease under 505(b)(2) NDA Pathway

Stock Information for Serina Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Serina Therapeutics Inc.

Serina Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Highlights
Serina Therapeutics Provides Regulatory Update on SER-252 Program
Serina Therapeutics Launches Enhanced Corporate Communications Platform to Strengthen Engagement with Patients, Clinicians, and Investors
Serina Therapeutics Draws First $5 Million Funding Tranche to Support Registrational Trial of SER-252 in Parkinson's Disease
Serina Therapeutics Secures Up to $20 Million to Advance Registrational Trial of SER-252 in Parkinson's Disease
Serina Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference
Serina Therapeutics Reports Second Quarter 2025 Financial Results and Provides Business Highlights
Serina Therapeutics Advances POZ-VMAT2i into Development for Tardive Dyskinesia (TD)

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.